Literature DB >> 31296578

Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.

Samer A Srour1, Amanda Olson1, Stefan O Ciurea1, Parth Desai2, Qaiser Bashir1, Betul Oran3, Prithviraj Bose1, Rohtesh Mehta4, Keyur P Patel5, Naveen Pemmaraju6, Naval Daver7, Srdan Verstovsek7, Richard E Champlin8, Uday R Popat7.   

Abstract

Entities:  

Year:  2021        PMID： 31296578      PMCID： PMC8252931          DOI： 10.3324/haematol.2019.223503

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  21 in total

1.  Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Authors:  Markus Ditschkowski; Ahmet H Elmaagacli; Rudolf Trenschel; Tanja Gromke; Nina K Steckel; Michael Koldehoff; Dietrich W Beelen
Journal:  Haematologica       Date:  2012-04-04       Impact factor: 9.941

2.  Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.

Authors:  Haefaa Alchalby; Anita Badbaran; Tatjana Zabelina; Guido Kobbe; Joachim Hahn; Daniel Wolff; Martin Bornhäuser; Christian Thiede; Herrad Baurmann; Wolfgang Bethge; York Hildebrandt; Ulrike Bacher; Boris Fehse; Axel R Zander; Nicolaus Kröger
Journal:  Blood       Date:  2010-05-20       Impact factor: 22.113

3.  Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation.

Authors:  Martin Bornhäuser; Uta Oelschlaegel; Uwe Platzbecker; Gesine Bug; Karin Lutterbeck; Michael G Kiehl; Johannes Schetelig; Alexander Kiani; Thomas Illmer; Markus Schaich; Catrin Theuser; Brigitte Mohr; Cornelia Brendel; Axel A Fauser; Stefan Klein; Hans Martin; Gerhard Ehninger; Christian Thiede
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

Review 4.  Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.

Authors:  N M Kröger; J H Deeg; E Olavarria; D Niederwieser; A Bacigalupo; T Barbui; A Rambaldi; R Mesa; A Tefferi; M Griesshammer; V Gupta; C Harrison; H Alchalby; A M Vannucchi; F Cervantes; M Robin; M Ditschkowski; V Fauble; D McLornan; K Ballen; U R Popat; F Passamonti; D Rondelli; G Barosi
Journal:  Leukemia       Date:  2015-08-21       Impact factor: 11.528

5.  Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.

Authors:  Nicolaus Kröger; Anita Badbaran; Ernst Holler; Joachim Hahn; Guido Kobbe; Martin Bornhäuser; Andreas Reiter; Tatjana Zabelina; Axel R Zander; Boris Fehse
Journal:  Blood       Date:  2006-10-03       Impact factor: 22.113

Review 6.  International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

Authors:  Ayalew Tefferi; Giovanni Barosi; Ruben A Mesa; Francisco Cervantes; H Joachim Deeg; John T Reilly; Srdan Verstovsek; Brigitte Dupriez; Richard T Silver; Olatoyosi Odenike; Jorge Cortes; Martha Wadleigh; Lawrence A Solberg; John K Camoriano; Heinz Gisslinger; Pierre Noel; Juergen Thiele; James W Vardiman; Ronald Hoffman; Nicholas C P Cross; D Gary Gilliland; Hagop Kantarjian
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

7.  Detection of relapse by sequential monitoring of chimerism in circulating CD34+ cells.

Authors:  Ch Thiede; K Lutterbeck; U Oelschlägel; M Kiehl; Ch Steudel; U Platzbecker; C Brendel; A A Fauser; A Neubauer; G Ehninger; M Bornhäuser
Journal:  Ann Hematol       Date:  2002       Impact factor: 3.673

8.  Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting.

Authors:  Evgeny Klyuchnikov; Ernst Holler; Martin Bornhäuser; Guido Kobbe; Arnon Nagler; Avichai Shimoni; Christian Könecke; Christine Wolschke; Ulrike Bacher; Axel R Zander; Nicolaus Kröger
Journal:  Br J Haematol       Date:  2012-08-22       Impact factor: 6.998

9.  Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation.

Authors:  Nina K Steckel; Michael Koldehoff; Markus Ditschkowski; Dietrich W Beelen; Ahmet H Elmaagacli
Journal:  Transplantation       Date:  2007-06-15       Impact factor: 4.939

10.  Guideline for the diagnosis and management of myelofibrosis.

Authors:  John T Reilly; Mary Frances McMullin; Philip A Beer; Nauman Butt; Eibhlean Conneally; Andrew Duncombe; Anthony R Green; N George Michaeel; Marie H Gilleece; Georgina W Hall; Steven Knapper; Adam Mead; Ruben A Mesa; Mallika Sekhar; Bridget Wilkins; Claire N Harrison
Journal:  Br J Haematol       Date:  2012-06-01       Impact factor: 6.998
View more
  3 in total

Review 1.  2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management.

Authors:  Haris Ali; Andrea Bacigalupo
Journal:  Am J Hematol       Date:  2021-10-05       Impact factor: 13.265

2.  Early Mixed Lymphoid Donor/Host Chimerism is Associated with Improved Transplant Outcome in Patients with Primary or Secondary Myelofibrosis.

Authors:  H Joachim Deeg; Rachel B Salit; Tim Monahan; Gary Schoch; Chris McFarland; Bart L Scott; Barry E Storer
Journal:  Biol Blood Marrow Transplant       Date:  2020-07-18       Impact factor: 5.742

3.  Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.

Authors:  Tania Jain; Katie L Kunze; Luke Mountjoy; Daniel K Partain; Heidi Kosiorek; Nandita Khera; William J Hogan; Vivek Roy; James L Slack; Pierre Noel; Veena D S Fauble; Jose F Leis; Lisa Sproat; Ayalew Tefferi; Mrinal M Patnaik; Ruben A Mesa; Jeanne Palmer
Journal:  Blood Cancer J       Date:  2020-03-10       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.